Malignant Neoplasm Clinical Trial
Official title:
Clinical Study of Descitabine Enhanced Infusion of Autologous DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
1. Screening stage
2. Evaluation of disease
3. Grouping of patients
4. Infusion of cells
5. Surveillance of adverse effect
1. Screening stage：All patients must be confirmed by pathology priorily and reachead
remission after surgery or chemo- or radiotherapy. All criteria patients must sign
informed consent in advance.
2. Evaluation of disease: Systematically assessment of tumor burdern and Physical fitness
of all patients.
3. Cell preparation：At least one month after the end of the last chemotherapy, 100ml of
peripheral blood was collected, and PBMCs were separated and extracted in the tens of
thousands and local hundreds of clean laboratories and DC-CIK cells were prepared.
4. Baseline assessment: Systematically assess various biochemical indicators. Those who do
not meet the infusion criteria will withdraw from the study after being confirmed by
researchers.
5. Study group: All subjects were randomly divided into test group and control group. The
test group was treated with decitabine. The course of treatment was a total of 5 times.
6. Infusion：During cell culture and before transfusion, cells should be subjected to strict
quality control tests such as bacteria, fungi, mycoplasma, endotoxin, cell activity, DC
and T cell identification, etc. The transfusion can be approved only after the quality
control is qualified.
7. Adverse reaction monitoring: DC-CIK infusion was used to closely observe changes in
subjects' blood pressure, body temperature, blood routine, blood biochemistry,
electrolytes, coagulation, cytokines and organ functions.
8. After the trial is completed, the patient's survival information will be followed up
every 3 months by telephone or by visiting the test center.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02243592 -
Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
|
||
| Completed |
NCT03445572 -
Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer
|
N/A | |
| Active, not recruiting |
NCT02860039 -
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
|
Phase 2 | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT01635413 -
Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)
|
N/A | |
| Completed |
NCT00026169 -
Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure
|
Phase 1 | |
| Recruiting |
NCT04534075 -
Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial
|
Phase 3 | |
| Active, not recruiting |
NCT01806129 -
Reproductive Health Program in Patients With Cancer
|
N/A | |
| Recruiting |
NCT03915717 -
Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
|
||
| Recruiting |
NCT02280161 -
Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
|
||
| Recruiting |
NCT05520281 -
Short-term Psychodynamic Psychotherapy in Serious Physical Illness
|
N/A | |
| Terminated |
NCT00532064 -
Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
|
||
| Completed |
NCT04990882 -
FAPI PET/CT Prospective Interobserver Agreement
|
||
| Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
| Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05886764 -
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
|
N/A | |
| Completed |
NCT01506440 -
Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy
|
||
| Completed |
NCT01432431 -
Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff
|
N/A |